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ARTICLE
Clinical Study
Plasma total cell-free DNA is a prognostic biomarker
of overall survival in metastatic solid tumour patients
Ida Viller Tuxen1, Lise Barlebo Ahlborn1,2, Morten Mau-Soerensen1, Kristoffer Staal Rohrberg1, Finn Cilius Nielsen2, Olga Oestrup2,
Christina Westmose Yde2, Ivan Richter Vogelius3 and Ulrik Lassen1
BACKGROUND: Selecting patients for early clinical trials is a challenging process and clinicians lack sufficient tools to predict overall
survival (OS). Circulating cell-free DNA (cfDNA) has recently been shown to be a promising prognostic biomarker. The aim of this
study was to investigate whether baseline cfDNA measurement could improve the prognostic information of the Royal Marsden
Hospital (RMH) score.
METHODS: Solid tumour patients referred for phase I trials were included in the Copenhagen Personalized Oncology (CoPPO)
programme. Baseline characteristics were collected prospectively, including the RMH prognostic score, Eastern Cooperative
Oncology Group (ECOG) performance status and concentration of cfDNA per millilitre plasma. Cox proportional hazards model was
used to assess the prognostic value of baseline variables.
RESULTS: Plasma cfDNA concentration was quantifiable in 302 patients out of a total of 419 included in the study period of 2 years
and 5 months. The RMH score was confirmed to be associated with OS. Cell-free DNA was shown to be an independent prognostic
marker of OS and improved the risk model, including RMH, performance status and age. Furthermore, both plasma cfDNA
concentration and RMH score were associated with treatment allocation (p < 0.00001).
CONCLUSION: Our model based on RMH score, age, ECOG performance status and cfDNA improved prediction of OS and
constitutes a clinically valuable tool when selecting patients for early clinical trials. An interactive version of the prognostic model
is published on http://bit.ly/phase1survival.
British Journal of Cancer (2019) 121:125–130; https://doi.org/10.1038/s41416-019-0491-9
BACKGROUND
Cancer patients with exhausted treatment options can be referred
to phase 1 clinical trials where the primary objectives are dose
finding and toxicity assessment. However, only a minority of
patients will benefit from treatment1,2 and selection of the most
appropriate patient for therapy is challenging. Generally used
eligibility criteria include adequate organ function, good perfor-
mance status and life expectancy more than 3 months. Clinicians
often misjudge the survival of the patients leading to screen
failures and waste of important time for the individual patient.3–5
Different prognostic scores have been introduced in order to
select patients for phase 1 trials.6,7 The Royal Marsden Hospital
(RMH) score has been validated in various phase 1 cohorts8–11 and
consist of three variables: Elevated lactate dehydrogenase (LDH)
(> upper limit), low serum-albumin (< 35 g/L) and more than two
metastatic sites. Although, these prognostic scores have been
validated, the clinical use is limited.
In recent years, much attention in oncological studies has been
given to circulating cell-free DNA (cfDNA) as a non-invasive tumour
marker used in diagnostics and treatment monitoring. Cell-free
DNA is short fragments of DNA present in plasma and other body
fluids and originates from apoptotic and necrotic cells representing
normal tissue and potentially multiple tumour lesions.12 cfDNA has
been highlighted as a new potential biomarker for overall survival
(OS) in various cancer subtypes.13–15 To investigate the clinical
utility of cfDNA in patients referred to phase 1 trials, we conducted
a pre-planned examination of baseline plasma cfDNA levels in
patients participating in the Copenhagen Prospective Personalized
Oncology (CoPPO) trial.16 The aim of the study was to investigate
whether additional measurements of plasma cfDNA concentration
improved the prognostic value of the RMH score and thus
selection of patients for phase I trials.
METHODS
Patients and study design
This study included patients enrolled in the CoPPO study
(NCT02290522) from October 2014–February 2017. The CoPPO
study aims to investigate the clinical utility of molecular profiling
to select patients for early clinical trials. All patients fulfilled the
inclusion criteria including: exhausted treatment options, life
expectancy ≥ 3 months, normal organ function, age ≥ 18 years,
Eastern Cooperative Oncology Group (ECOG) performance status
0 or 1 and lesions assessable for biopsy. Basic characteristics
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including serum albumin and lactate dehydrogenase (LDH)
were registered at inclusion. Values obtained within 2 months of
inclusion were accepted.
The study was conducted in accordance with the Declaration
of Helsinki and approved by the Danish Data Protection Agency
and the Regional Ethics Committee (Danish Ethical Committee,
file number: 1300530). All patients provided signed informed
consent. Cut-off date was 22 February 2018. Examination of
plasma cfDNA concentration was planned but the statistical
analysis was not pre-specified and thereby considered as
exploratory.
Extraction and quantification of cfDNA
Peripheral blood was collected in cell-stabilising Blood Collec-
tion Tubes (BCT; Streck Laboratories, Omaha, NE, USA) and
cfDNA was extracted from 2–4 millilitre (ml) plasma using the
QIAsymphony Circulating DNA Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions using an elution
volume of 60 µl as previously described.17 Quantification of
cfDNA was performed using the dsDNA HS Assay Kit (> 10 pg/µL)
on a Qubit Fluorometer (Thermo Fisher Scientific, Waltham, MA)
and the concentration of cfDNA per ml of plasma was calculated
for each sample.18
For validation of the cfDNA quantification method, we
measured total cfDNA in triplicates using the Agilent 4200
TapeStation system (D5000) for 49 samples with low cfDNA
concentration (0–15 ng/ml plasma (A)) and 47 samples with
high concentration (50–1000 ng/ml plasma (B)) (Fig. S2). For
the high-concentration group we diluted samples (1:10) if the
concentration was >100 ng/ml plasma. The Agilent 4200
TapeStation system (D5000) uses electrophoresis to separate
DNA fragments from 100–5000 bp and can quantify DNA
concentrations down to 0.1 ng/µL. In contrast, the Qubit system
uses intercalating fluorescent dyes binding only double
stranded DNA, leading to concentration measures around half
the value of the ones from the TapeStation. This was supported
by the Bland–Altman plot shown in Fig. S3 illustrating the
concordance between Qubit and TapeStation cfDNA quantifica-
tion (mean percentage difference between the methods of
21.8% and limits of agreement around ± 40%).
Statistical analysis
OS (Kaplan–Meier) was calculated from the date of inclusion to
time of death or censure. The prognostic value of the RMH score
was tested using a univariate Cox model with RMH score as
scale input. Subsequently, multivariable analysis was performed
with performance status and RMH score as predefined categorical
covariables. Age and the log-transformed value of cfDNA
(logcfDNA) from the Qubit system was included as continuous
variables. Coding (e.g. logcfDNA) was confirmed by comparison
with restricted cubic spines.
Correlations between the covariables RMH score, age and
logcfDNA were assessed visually and the validity of the propor-
tional hazards assumption on performance status and RMH score
was investigated by visual assessment of log minus–log survival
curves. Statistical analysis was performed in R using the cph-
function of the RMS package.19 In all cases a p-value of 0.05 or less
was considered significant. The final model is published as an
interactive version using the Shiny package in R.20 We tested a
possible association between cfDNA (quartiles)/RMH score and the
risk of not being offered treatment using logistic regression by
glm package in R treating both cfDNA quartiles (25th percentile:
7.4 ng/ml; 50th percentile: 17.1 ng/ml; 75th percentile: 39.55 ng/
ml) and RMH score as a numerical covariate.
RESULTS
Patient characteristics
A total of 419 patients were included in the CoPPO study within the
study period. Measurable plasma cfDNA concentration at inclusion
was obtained from 302 patients and 169 patients were allocated
to treatment and 133 received no further treatment (Fig. 1).
No. of treatment
Patients biopsied
Patients with measurable cfDNA at inclusion
Treatment
N = 419
N = 302
N = 169
N = 62 N = 33 N = 74
Patients excluded
No. of cfDNA collected, N = 68
CfDNA not analysed, N = 18
No. of cfDNA at inclusion, N = 12
Failed cfDNA analysis, N = 19
Protocol Off-label Other
N = 133
Fig. 1 Patient flowchart. A total of 419 patients were included within the study time (3 October 2014 to 22 February 2017) including 302
patients with available plasma cfDNA samples collected at the time of tissue biopsy (baseline). A total of 169 patients were allocated to
treatment whereas 133 patients received no further treatment
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Baseline patient characteristics are summarised in Table 1. There
was an equal distribution of gender and age. Patients had received
a median of three prior treatment regimens and the majority
of patients (63%) presented with more than two metastatic
sites. Baseline LDH was elevated in 196 patients (65%) and 168
patients (56%) presented with serum-albumin below normal
level. In total, one third of the patients (32%) were classified as
having a good prognostic score (RMH score 0–1) with most patients
having a performance score of 1 (66%) according to ECOG
guidelines. Median OS was 24 weeks (95% CI 21.0–27.0) and
median follow-up time of censored cases (n= 35) was 84 weeks
(CI 73.6–94.4). The most common tumour types were colorectal
cancer (25%), followed by breast (12%), pancreatic (9%) and
bile duct cancers (8%) (Table S1). Plasma concentration of cfDNA
according to cancer subtype is reported in Fig. 2 with an overall
median of 17.1 ng/ml (1.1—795.0) (Table S1). Both RMH score
and cfDNA quartile was highly associated with the probability
of not being offered treatment (Fig. 3, P < 0.00001 for both RMH
score and cfDNA).
Prognostic value of cfDNA on survival
Univariate survival analysis. We confirmed a clear association
between the RMH score and OS (log-rank P < 0.0001) (Fig. 4a).
Univariate survival for the four quartiles of cfDNA showed
a significant association between cfDNA levels and OS (log-rank
P < 0.0001) (Fig. 4b). No correlations were observed between
RMH score, performance status and the age of the patients.
Furthermore, there was no correlation between RMH score
and cfDNA (Fig. S1).
Multivariate survival analysis. In multivariate analysis including
age, RMH, performance status and logcfDNA, low plasma
concentration of cfDNA was associated with longer OS with a
Table 1. Patient characteristics
Total
(n= 302)
Gender
Female 145 (48%)
Male 157 (52%)
Age
Median, range 60 (26–86)
Metastatic sites
≤2 111 (37%)
>2 190 (63%)
Missing 1 (0%)
Albumin
≥35 g/L 129 (43%)
<35 g/L 168 (56%)
Missing 5 (2%)
LDH
>ULN 196 (65%)
≤ULN 104 (34%)
Missing 2 (1%)
RMH score
0–1 97 (32%)
2–3 200 (66%)
Missing 5 (2%)
Number of prior treatment regimens
Median, range 3 (1–11)
Performance status (ECOG)
0 99 (33%)
1 200 (66%)
2 3* (1%)
*Patients declining in performance status from inclusion to the time
of biopsy
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Fig. 2 Distribution of cfDNA concentrations (ng/ml plasma) in diverse cancer subtypes. Cancer types including five or more patients are
indicated with cfDNA concentrations and the median value for each subtype is indicated by a horizontal line. Each dot represents a patient
included in the study
Plasma total cell-free DNA is a prognostic biomarker of overall survival. . .
I Viller Tuxen et al.
127
hazard ratio (HR) of 1.67 (95% CI: 1.39–2.01; P < 0.0001). No
association between age and survival was observed (Table 2).
The OS curves variate according to altering concentrations of
cfDNA although RMH score remains the same. An interactive
version of the prognostic model is published on http://bit.ly/
phase1survival and presented in Fig. S4 by a typical patient from
the cohort aged 60 years, RMH score= 2, performance status= 1
and cfDNA levels of 20 and 100 ng/ml plasma.
DISCUSSION
Clinicians treating patients with exhausted treatment options
are facing the dilemma of choosing when to refer the patient
to early clinical trials. The RMH score can be used as a prognostic
score to guide this decision. In this study, we have shown that
by adding the baseline measurement of plasma cfDNA concen-
tration, performance status and age to the RMH score, we
were able to build a stronger prediction model assessing OS.
This model showed superiority compared to RMH score alone.
An improved risk assessment could support the clinical decision
when enrolling patients in phase I studies as early discontinua-
tion of patients in phase 1 trials most frequently are due
to progression and clinical deteoriation.21 The clinical imple-
mentation of the proposed model therefore has the potential
to improve selection of patients to phase I trials. Furthermore,
low plasma concentration of cfDNA at baseline is correlated with
a higher chance of receiving further treatment. Similar results
were observed with RMH score, suggesting that both markers
could be valuable tools in allocating patients to treatment in
a phase 1 setting.
Our patient cohort represented a consecutive group of patients
included in a molecular profiling project with most patients not
receiving treatment within a clinical trial (Fig. 3). It seems likely,
that this cohort is representative for a typical cohort of patients
referred to phase 1 trials.
However, there are limitations to this study; this is a single
centre study and the risk model requires validation in other
phase 1 cohorts. Furthermore, we could not exclude whether
treatment affected the survival analysis. Low concentrations
of cfDNA (< 5 ng/ml) can be measured in healthy individuals
mostly emerging from haematopoietic cells22 and the concen-
tration of cfDNA can be influenced by other factors including
inflammation, infectious disease, exercise etc. These are all
confounders of our model and must be considered. For clinical
use we would recommend the blood samples to be collected
without prior physical activity and notion of an infection. In
addition, we only used one method to quantify the cfDNA
concentrations. The fluorescence-based Qubit HS assay was
selected as this is a simple, fast, cheap and standard method
used in most clinical laboratories. Similar assays using inter-
calating fluorophores have been widely used to detect
low levels of cfDNA18,23 but other methods are being validated
to optimise the accuracy of cfDNA quantification including
digital and real-time PCR.24,25 Larger studies comparing the
different methods are needed to standardise the quantification
of cfDNA.
Total cfDNA have previously been shown as a prognostic factor
in selected cancer types13–15 but, to our knowledge, never used to
predict survival in the phase 1 setting across a wide range of
cancer types. Additionally, cfDNA has never been added to the
RMH score and our data support the addition of cfDNA to improve
prediction of survival compared to RMH alone. Olmos et al. have
shown that adding the number of circulating tumour cells (CTCs)
to the RMH score, improved estimation of OS.26 However, this has
not been implemented in clinical practice, probably due to the
laborious process of isolating CTCs.
In conclusion, we present a model based on a single-
centre study, that offers a valuable supplement to the RMH
score providing a further improved estimation of the OS for
the individual patient. This study supports the continuing efforts
exploring the clinical role of cfDNA in cancer care.
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Table 2. Cox proportional hazards model
Hazard ratio (95% CI) P-value
Age 0.97 (0.82–1.16) 0.77
cfDNA [log] 1.67 (1.39–2.01) <0.0001
RMHI 1 vs. 0 2.08 (1.22–3.57) 0.008
RMHI 2 vs. 0 2.29 (1.38–3.80) 0.001
RMHI 3 vs. 0 3.57 (2.12–6.03) <0.0001
PS 1 vs. 0 2.35 (1.77–3.13) <0.0001
Plasma total cell-free DNA is a prognostic biomarker of overall survival. . .
I Viller Tuxen et al.
129
informed consent and the study was performed in accordance with the Declaration
of Helsinki.
Funding: We thank the Capital Region of Copenhagen and the Oncological Research
Fund, Department of Oncology, Copenhagen University Hospital, Denmark for
financial support.
Data availability: Data is available as Supplementary material. An interactive version
of the prognostic model is published on http://bit.ly/phase1survival
Note: This work is published under the standard license to publish agreement.
After 12 months the work will become freely available and the license terms
will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. Horstmann, E., McCabe, M. S., Grochow, L., Yamamoto, S., Rubinstein, L., Budd, T.
et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N. Engl. J.
Med. 352, 895–904 (2005).
2. Schwaederle, M., Zhao, M., Jack Lee, J., Lazar, V., Leyland-Jones, B., Schilsky, R. L.
et al. Association of biomarker-based treatment strategies with response rates
and progression-free survival in refractory malignant neoplasms a meta-analysis.
JAMA Oncol. 2, 1452–1459 (2016).
3. Bachelot T. D., Catimel G., Ardiet C., Guastalla J. P., Dumortier A., Chauvin F. et al.
Multivariable analysis of prognostic factors for toxicity and survival for patients
enrolled in phase I clinical trials. Ann Oncol. 11, 151–156 (2000)
4. Ploquin, A., Olmos, D., Ferté, C., Cassier, P. A., Kramar, A., Duhamel, A. et al. Life-
expectancy of patients enrolled in phase 1 clinical trials: a systematic review of
published prognostic models. Crit. Rev. Oncol. Hematol. 83, 242–248 (2012).
5. Ploquin, A., Olmos, D., Lacombe, D., A’Hern, R., Duhamel, A., Twelves, C. et al.
Prediction of early death among patients enrolled in phase I trials: development
and validation of a new model based on platelet count and albumin. Br. J. Cancer
107, 1025–1030 (2012).
6. Arkenau, H.-T., Barriuso, J., Olmos, D., Ang, J. E., de Bono, J., Judson, I. et al.
Prospective validation of a prognostic score to improve patient selection for
oncology phase I trials. J. Clin. Oncol. 27, 2692–2696 (2009).
7. Wheler, J., Tsimberidou, A. M., Hong, D., Naing, A., Falchook, G., Piha-Paul, S. et al.
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for
targeted therapy experience. Clin. Cancer Res. 18, 2922–2929 (2012).
8. Arkenau, H. T., Olmos, D., Ang, J. E., De Bono, J., Judson, I. & Kaye, S. Clinical
outcome and prognostic factors for patients treated within the context of a
phase I study: the Royal Marsden Hospital experience. Br. J. Cancer 98, 1029–1033
(2008).
9. Chau, I., Ashley, S. & Cunningham, D. Validation of the Royal Marsden hospital
prognostic index in advanced esophagogastric cancer using individual patient
data from the REAL 2 study. J. Clin. Oncol. 27, e3–e4 (2009).
10. Garrido-Laguna, I., Janku, F., Vaklavas, C., Falchook, G. S., Fu, S., Hong, D. S. et al.
Validation of the Royal Marsden Hospital prognostic score in patients treated in
the phase I clinical trials program at the MD Anderson Cancer Center. Cancer 118,
1422–1428 (2012).
11. Livingston, J. A., Hess, K. R., Naing, A., Hong, D. S., Patel, S., Benjamin, R. S. et al.
Validation of prognostic scoring and assessment of clinical benefit for patients
with bone sarcomas enrolled in phase I clinical trials. Oncotarget 7, 64421–64430
(2016).
12. Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F. O., Hesch, R. D. et al. DNA
fragments in the blood plasma of cancer patients: quantitations and evidence
for their origin from apoptotic and necrotic cells. Cancer Res. 61, 1659–1665
(2001).
13. Cheng, J., Holland-Letz, T., Wallwiener, M., Surowy, H., Cuk, K., Schott, S. et al.
Circulating free DNA integrity and concentration as independent prognostic
markers in metastatic breast cancer. Breast Cancer Res. Treat. 169, 69–82 (2018).
14. Valpione, S., Gremel, G., Mundra, P., Middlehurst, P., Galvani, E., Girotti, M. R. et al.
Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden
and a prognostic biomarker for survival in metastatic melanoma patients.
Eur. J. Cancer 88, 1–9 (2018).
15. Mehra N., Dolling D., Sumanasuriya S., Christova R., Pope L., Carreira S., et al.
Plasma cell-free DNA concentration and outcomes from Taxane therapy in
metastatic castration-resistant prostate cancer from two phase III trials
(FIRSTANA and PROSELICA). Eur. Urol. 74, 283–291 (2018)
16. Tuxen I. V., Santoni-Rugiu E., Joenson Lars, Vikesaa J., Mau-Sørensen M., Nielsen F.
C., et al. Copenhagen prospective personalized oncology (CoPPO): sequencing
and array-based pipeline for selection of patients to phase 1 studies. J Clin. Oncol.
32, 11097 (2014).
17. Ahlborn, L. B., Madsen, M., Joenson, L., Nielsen, F. C., Lassen, U., Yde, C. W.
et al. Concordance of mutation detection in circulating tumor DNA in early
clinical trials using different blood collection protocols. Clin. Lab. 63, 1755–1759
(2017).
18. Kloten, V., Rüchel, N., Brüchle, N. O., Gasthaus, J., Freudenmacher, N., Steib, F.
et al. Liquid biopsy in colon cancer: comparison of different circulating DNA
extraction systems following absolute quantification of KRAS mutations using
Intplex allele-specific PCR. Oncotarget 8, 86253–86263 (2017). 21.
19. Harrel F. E. rms: Regression Modeling Strategies. https://cran.r-project.org/
package=rms. (2018).
20. Chang W., Cheng J., Allaire J., Xie Y. & McPherson J. shiny: Web Application
Framework for R. https://cran.r-project.org/package=shiny. (2018).
21. Kempf, E., Lemoine, N., Tergemina-Clain, G., Turpin, A., Postel-Vinay, S., Lanoy, E.
et al. A case-control study brings to light the causes of screen failures in phase 1
cancer clinical trials. PLoS ONE 11, e0154895 (2016).
22. Lui, Y. Y. N. & Lo, Y. M. D. Circulating DNA in plasma and serum: Biology, pre-
analytical issues and diagnostic applications. Clin. Chem. Lab. Med. 40, 962–968
(2002).
23. Fleischhacker M. & Schmidt B. Circulating nucleic acids (CNAs) and cancer—a
survey. Biochim. Biophys. Acta. 1775, 181–232 (2007)
24. Devonshire, A. S., Whale, A. S., Gutteridge, A., Jones, G., Cowen, S., Foy, C. A. et al.
Towards standardisation of cell-free DNA measurement in plasma: controls for
extraction efficiency, fragment size bias and quantification. Anal. Bioanal. Chem.
406, 6499–6512 (2014).
25. Dietz S., Schirmer U., Mercé C., Von Bubnoff N., Dahl E., Meister M., et al. Low
input whole-exome sequencing to determine the representation of the tumor
exome in circulating DNA of non-small cell lung cancer patients. PLoS ONE 11,
e0161012 (2016).
26. Olmos, D., Baird, R. D., Yap, T. A., Massard, C., Pope, L., Sandhu, S. K. et al. Baseline
circulating tumor cell counts significantly enhance a prognostic score for
patients participating in phase I oncology trials. Clin. Cancer Res. 17, 5188–5196
(2011).
Plasma total cell-free DNA is a prognostic biomarker of overall survival. . .
I Viller Tuxen et al.
130
